14 According to our patent searches, Novo Nordisk has filed 91 patents for formulations, 41 patents covering devices to deliver the drug, and 45 patents for methods of treatment (Figure 6)
More recently, encouraging clinical results from a triple-hormone-receptor agonist, Retatrutide, and several GLP-1R/GCGR dual agonists, suggest that GCGR could be a promising co-stimulating target for type 2 diabetes and obesity
Research shows that Wegovy may be the better choice for weight loss because it goes up to 2.4 mg weekly as an injectable and up to 25 mg as a pill
You can administer the injections at home or at your doctors office
Glucagon influences bile acid metabolism, and altered bile acid patterns in the intestines are a well-known trigger for osmotic diarrhea
On the 12mg maintenance dose, participants lost an average of 28.7% of body weight versus 2.1% on placebo, as reported by Eli Lilly in December 2025 (peer-reviewed publication pending)